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Sung Yoon Cho,1,18 Jun-Seok Bae,2,3,18 Nayoung K.D. Kim,2 Francesca Forzano,4 Katta Mohan Girisha,5
Chiara Baldo,6 Francesca Faravelli,4 Tae-Joon Cho,7 Dongsup Kim,8 Kyoung Yeul Lee,8 Shiro Ikegawa,9
Jong Sup Shim,10 Ah-Ra Ko,11 Noriko Miyake,12 Gen Nishimura,13 Andrea Superti-Furga,14
Ju¨rgen Spranger,15 Ok-Hwa Kim,16 Woong-Yang Park,2,3,17,* and Dong-Kyu Jin1,*
Spondyloepimetaphyseal dysplasias (SEMDs) comprise a heterogeneous group of autosomal-dominant and autosomal-recessive disor-
ders. An apparent X-linked recessive (XLR) form of SEMD in a single Italian family was previously reported.We have been able to restudy
this family together with a second family from Korea by segregating a severe SEMD in an X-linked pattern. Exome sequencing showed
missense mutations in BGN c.439A>G (p.Lys147Glu) in the Korean family and c.776G>T (p.Gly259Val) in the Italian family; the
c.439A>G (p.Lys147Glu) mutation was also identified in a further simplex SEMD case from India. Biglycan is an extracellular matrix
proteoglycan that can bind transforming growth factor beta (TGF-b) and thus regulate its free concentration. In 3-dimensional
simulation, both altered residues localized to the concave arc of leucine-rich repeat domains of biglycan that interact with TGF-b.
The observation of recurrent BGN mutations in XLR SEMD individuals from different ethnic backgrounds allows us to define ‘‘XLR
SEMD, BGN type’’ as a nosologic entity.Spondyloepimetaphyseal dysplasias (SEMDs) are charac-
terized by anomalies of the spine and the epiphyses and
metaphyses of the long bones, resulting in short stature
and osteoarthritic changes of the joints. In 1994, X-linked
SEMD (MIM: 300106) was described by Camera et al.1 in
eight male individuals from six generations of an Italian
family. Recently, we encountered a Korean family in which
male siblings and their grandfather exhibited radiological
features of SEMD. The older brother of the male siblings
was suspected to have pseudoachondroplasia (MIM:
177170); however, no mutation was found in COMP
(MIM: 600310). An Indian person subsequently referred
for radiological diagnosis showed the phenotype similar
to those of Italian and Korean individuals.
We analyzed Korean (Figure 1A) and Italian (Figures 1B)
families with multiple affected males and one simplex In-
dian individual (Figure 1C) (see case reports in Supple-
mental Data). All affected individuals were born at term
from healthy non-consanguineous parents. The birth
weights and birth lengths were within the normal range.
All persons came to medical attention between 12 and
24 months of age because of growth retardation with
body disproportion (Table 1). They showed resomelic1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan Universi
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 2016 American Society of Human Genetics.shortening of the limbs and short limbs-to-trunk ratio.
The affected individuals showed significant bowing of
the legs, a waddling gait with lumbar lordosis, and brachy-
dactyly. Their facial appearance, teeth, and sclerae were
unremarkable, as were their cognitive development and
intelligence. The data from biological tests (i.e., routine
blood cell count, blood and urinary levels of calcium,
phosphate, creatinine, serum alkaline phosphatase, 25-hy-
droxyvitaminD, parathyroid hormone, and urine analysis)
were within the normal range. The originally described1
Italian individuals (V-8, V-9, and VI-6) have been regularly
visited since 1994. Individual VI-6 underwent 15 orthope-
dic procedures to lengthen both the femora and the tibiae
since adolescence, when his height was 122 cm, and his
final height after successful orthopedic procedures was
160 cm. His gait was almost normal, and he could swim.
Obligate carriers V-6 and V-10 showed no specific health
problems except hypertension in later adulthood. A pic-
ture of the Italian family taken in 2015 is shown in
Figure S1. Adult Korean and Italian individuals were rela-
tively healthy except for hypertension after the age of 60
years. They had life-sustaining occupations, enjoyed hik-
ing and bicycling, walked without support, and had noty School of Medicine, Seoul 06351, Republic of Korea; 2Samsung Genome
icine, Seoul 06351, Republic of Korea; 3Department of Health Sciences and
, Samsung Medical Center, Sungkyunkwan University School of Medicine,
ital, Via Volta 6, Genova 16128, Italy; 5Department of Medical Genetics,
tory of Human Genetics, Galliera Hospital, Genova 16128, Italy; 7Division
03080, Republic of Korea; 8Department of Systems Biology, Korea Advanced
ratory for Bone and Joint Diseases, RIKEN Center for Integrative Medical
ung Medical Center, Sungkyunkwan University School of Medicine, Seoul
esearch Center, Seoul 06351, Republic of Korea; 12Department of Human
236-0004, Japan; 13Department of Pediatric Imaging, Tokyo Metropolitan
atrics, Centre Hospitalier Universitaire Vaudois, University of Lausanne
ermany; 16Department of Radiology, Woorisoa Children’s Hospital, Seoul
kwan University School of Medicine, Suwon 16419, Republic of Korea
D.-K.J.)
an Journal of Human Genetics 98, 1243–1248, June 2, 2016 1243
Figure 1. Pedigree of Three Families
Showing the Segregation of BGN Mutant
Alleles
Shown are the pedigrees of the Korean
family (A), the Italian family (B), and the
Indian individual (C). Open boxes re-
present healthy males, and open circles
represent healthy females. Filled boxes
represent affected males. Boxes or circles
with a line across indicate that the person
has died. All circles with a dot in the
middle indicate the status of carrier.
Alleles with the wild-type genotype are
indicated by a plus sign. Samples were
not available for individuals lacking a ge-
notype designation.symptoms or signs of early arthritis or neurological issues.
The Indian individual (III-4) was 10 years old at the time of
our evaluation. His height was 103 cm (5.58 SDS). He had
no family members showing severe short stature.
Radiographs of the Korean and Indian boys showed
platyspondyly with central protrusion of the anterior
vertebral bodies, kyphotic angulation, and increased
lumbar lordosis. Radiographs showed flared ilia with hor-
izontal and irregular acetabular roofs and long and con-
stricted femoral necks (Figures 2A and 2C). The long
bones were very short with dysplastic epiphyses and
flared, irregular, and cupped metaphyses. Uniform short-
ness of the metacarpals and phalanges with coning at the
metacarpals was seen in affected children and adults
(Figure 2B). These findings were similar to those in the
previous report.1
To identify the pathogenic mutation, we screened the
germline genetic variations of the three families with array
comparative genome hybridization (aCGH). Using aCGH,
we examined copy-number alteration in the affected indi-
viduals and selected unaffected family members (IV-1,
III-1, and III-2 of the Korean family; V-8, V-9, and V-10 of
the Italian family; and III-4, II-3, and II-4 of the Indian
family), but no candidate gross aberration was detected.
Next, whole-exome sequencing (WES) was conducted to
identify the causal variants in nine members of two
different families (Korean and Italian). Written informed
consent was obtained from the individuals or their par-
ents, and the Institutional Review Board approved this
study (IRB file number: 2014-09-095-002).
The detailed methods of WES and the quality of
WES data are summarized in Tables S1 and S2. Based on1244 The American Journal of Human Genetics 98, 1243–1248, June 2, 2016the hypothesis that this disease is in-
herited in an XLR fashion, we elimi-
nated nonpathogenic variants with
our own script according to the
following conditions (Table S3): (1)
variants showing allele frequency
more than 1% in ESP6500 or 1000
Genomes Project; (2) variants found
in our in-house controls (n ¼ 452);
(3) synonymous amino acid changes; and (4) low quality
of reads (read number < 20, QS < 30, or minor allele
frequency < 20%).
Considering the clinical and radiological findings of two
families, skeletal dysplasia with severe short stature such as
SEMD aggrecan type (MIM: 612813), Dyggve-Melchior-
Clausen disease (MIM: 223800), acromesomelic dysplasia,
Maroteaux type (MIM: 602875), pseudoachondroplasia,
and spondyloepiphyseal dysplasia, Maroteaux type
(MIM: 184095) should be checked. No significant variation
was found in genes associated with these disorders (ACAN,
DMY, NPR2, COMP, and TRPV4) in affected individuals;
moreover, mutations in these genes are transmitted by
autosomal-dominant or -recessive mode.
In the Korean family, among the six genes found
in all affected individuals, one variant, c.439A>G
(p.Lys147Glu) in BGN (RefSeq: NM_001711.4), was identi-
fied as a possible XLR candidate after segregation analysis
using other Korean family members’ blood samples. In
the Italian family, the two genes carried variants in
all affected members, but one variant, c.776G>T
(p.Gly259Val) in BGN, was identified as a possible candi-
date after a segregation test. After combining the variants
selected by the XLR mutation model, the gene shared
by individuals from two families was found to be BGN
(Table S3). Interestingly, the same BGN variant as was
found in Korean individuals, c.439A>G (p.Lys147Glu),
was identified de novo in the Indian person. Neither of
these two variants in BGN was found in 904 control
chromosomes from individuals of Korean descent in
addition to 800 control chromosomes from individuals
of Japanese descent. These variants were not observed in
Table 1. Clinical Findings of the Affected Individuals with XLR SEMD BGN Type
Family F1 (Korean) F2 (Italian) F3 (Indian)
Subject IV-1 IV-2 II-1 II-2 II-6 V-8 V-9 VI-2 III-4
Age at onset of symptoma 12 months 15 months <2 years <2 years <2 years 18 months 18 months 18 months around 2 years
Age at exam 5 years 1 month 2 years 9 months 72 years 70 years 60 years 52 years (73 yearsb) 50 years (51 yearsb) 25 years (46 yearsb) 10 years
Height at exam (cm) (SD) 90 (4.17) 79.6 (3.56) 115 (9.67) 113 (10) 115 (9.67) 119 (8.98) 125 (7.95) 131 (6.91)c 103 (5.58)
Weight at exam (kg) (SD) 17.1 (0.78) 13.5 (0.83) ND ND ND 68 (0.51) 58 (0.55) ND 30 (1.15)
Mesomelic short limbs þ þ þ þ þ þ þ þ þ
Genu varum þ þ þ þ þ þ þ þ þ
Lumbar lodosis þ þ þ þ þ þ þ ND 
Brachydactyly þ þ þ þ þ þ þ þ þ
Joint laxity þ þ þ þ þ    
Waddling gait þ þ þ þ þ þ þ þ þ
Episode of fractures       þd þe 
Current medication   AHD AHD AHD AHD AHD  
Intelligence N N N N N N N N N
BGN mutation c.[439A>G];[0] c.[439A>G];[0] ND c.[439A>G];[0] c.[439A>G];[0] c.[776G>T];[0] c.[776G>T];[0] c.[776G>T];[0] c.[439A>G];[0]
All affected individuals had no hypotonia, limitation of movement, joint pain during childhood, early degenerative osteoarthritis, dentinogenesis imperfecta, hyperextensibility, visual difficulty, hearing difficulty, or neurologic
abnormalities. Abbreviations are as follows: N, normal; ND, not described; SDS, standard deviation score; DI, dentinogenesis imperfecta; AHD, antihypertensive drug.
aDisproportionately short stature with markedly bowed legs.
bFollow up examination in 2015.
c160 (1.91) cm after surgery.
dFracture of femur secondary to accidental trauma at 60 years.
eVarious fractures after lengthening of the lower limbs.
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Figure 2. Radiologic Characteristics of Individuals with XLR
SEMD BGN Type
(A) Korean family member IV-1’s radiographs at age 5 years. Spine
lateral shows platyspondyly with beaking appearance of its an-
terocentral portion and accentuated lordotic spinal curve. Note
brachymetacarpals and phalanges and delayed carpal bone ages.
Metaphyseal flaring and cupping are noted at the distal radii and
ulnae. Pelvis shows flared iliac wings with flat acetabuli. The
femoral necks are constricted and elongated. Small and dysplastic
capital femoral epiphyses are seen. Note marked metaphyseal flar-
ing and cupping of the lower extremity.
(B) Korean family member II-2, grandfather of IV-1, radiographs at
age 70 years. Lateral spine shows platyspondyly and anterior
wedging at L1 and L2 vertebral bodies, with kyphosis at the thor-
acolumbar spine. Hands show uniform brachydactyly, especially
brachymetacarpals. Pelvis reveals flared iliac wings and constricted
femoral necks. Hip joints are preserved for his age. Marked
shortening of the femora, tibiae, and fibulae with metaphyseal
widening are noted. Knee joints are intact.
(C) Indian family 3, a simplex case, radiographs at 10 years of age.
Lateral spine shows platyspondyly with residue of anterior beak-
ing.Wedging is noted at L1 vertebral body. Pelvis shows flared iliac
wings with flat and irregular acetabuli. Femoral necks are con-
stricted and elongated, and dysplastic capital femoral epiphyses
with lateral subluxation are seen.Metaphyseal flaring and cupping
are noted at the distal femoral and proximal tibiae with impinging
epiphyses within cupping metaphyses. Hands show uniformly
short metacarpals and phalanges and markedly delayed bone age.the ExAC database. The two variants in BGN have been
validated by Sanger sequencing of three different ethnic
family members (Figure S2).1246 The American Journal of Human Genetics 98, 1243–1248, JuneBiglycan, a member of the class I family of small
leucine-rich proteoglycans (SLRPs) in the extracellular
matrix, is highly expressed in bone.2,3 It is an important
structural component of articular cartilage and partici-
pates in the assembly of the chondrocyte extracellular
matrix through the formation of protein interactions
with type VI collagen and large proteoglycan aggregates.
Biglycan also plays a role in cell signaling, and it is
thought to play a critical role in the regulation of
chondrocyte and pericellular matrix homeostasis.4 Its
disruption affects postnatal skeletal growth and bone
formation5 by disturbing key signaling pathways and
the activity of the multifunctional cytokines TGF-b,6
bone morphogenic protein 4 (BMP4),7,8 and WNT.9 In
addition, BGN regulates osteoblast differentiation medi-
ated by the extracellular signal-regulated kinase (Erk)-
activated Runx2 pathway and activation of SMAD1/5/8
pathway.10 On this basis, abnormalities of biglycan are
expected to cause a skeletal dysplasia. This has now
been delineated. In accordance with these findings,
Bgn-deficient mice (bgn/0) show a reduced growth rate
and low bone mass that is not expressed at birth but
becomes obvious with age.5 X-ray images show short
tubular bones with decreased radiodensity compared
with age-matched controls. Histological analysis reveals
reduced trabeculation and cortical thickness.5 The
comparison of phenotypes between affected humans
with BGN mutation and Bgn knockout mice is shown in
Table S4.
Biglycan has two unique structural motifs: cystein
repeated sequence and leucine-rich repeat (LRR) defined
as a consensus sequence with leucines in conserved posi-
tions.11 The identified variant residues (Lys147 and
Gly259) are located in LRR and conserved in decorin,
which is in the same class I SLRP family as biglycan
(Figure 3A). The two residues are conserved in LRR motif
in different species as well as in different SLRP proteins.
To determine the structural properties of biglycan and its
mutated protein, we created a 3-dimensional (3D) model
of human biglycan using the crystal structure of bovine
biglycan as a template. We assumed that there are two
possible scenarios that could explain the pathogenicity
of two substitutions, p.Lys147Glu and p.Gly259Val. One
scenario consists of the decrease of biglycan stability
caused by physical impact of the point mutation on the
overall biglycan structure. The other predicts the interfer-
ence of the substitution with the binding interaction
between biglycan and TGF-b, which is known to bind
with biglycan.12,13
To investigate the decrease of protein stability, each
substituted monomer model was analyzed with Gromacs
Molecular Dynamics (MD) simulation. The visualization
of the altered residues on 3D structures is shown for the
two substitutions. To evaluate the probability of interfer-
ence with binding interaction, we performed a global
docking simulation between biglycan and TGF-b to build
a complex model. The complex models were compared2, 2016
Figure 3. Pathogenic Variant in BGN and
Molecular Interactions between Biglycan
and TGF-b
(A) The schematic diagram of BGN and
the position of two identified variants.
The two BGN variants (c.439A>G
[p.Lys147Glu]andc.776G>T[p.Gly259Val])
are located in the leucine-rich repeat (LRR)
domain. The asterisk (*) marks conserved
amino acid residue in biglycan (BGN) and
decorin (DCN). Boxed amino acid residues
indicate conserved functional leucine in
the LRR domain.
(B) Structural change brought about
two substitutions (p.Lys147Glu and
p.Gly259Val) predicted by molecular dy-
namics simulation. Arrows atmerged struc-
tures indicate the place where beta sheets
at the biglycan (BGN) concave region are
significantly perturbed by mutations.
(C) Structural model of BGN (green)
and TGF-b (blue) dimer. Red functional
residues indicate the substituted sites
(p.Lys147Glu).
(D) Structure simulation models for BGN p.Lys147Glu with TGF-b in overall and interface close-up view. Yellow dotted lines in close-up
view show polar interactions between functional groups around Glu147. Abbreviations are as follows: WT, wild-type biglycan; SUB,
substituted biglycan.between wild-type and the two variants. If the position of
the substitution did not appear to be located at the binding
interface between biglycan and TGF-b (as in the case of
p.Gly259Val), we also performed MD simulation for the
complex model.
According to the result of the MD simulation, both
p.Lys147Glu and p.Gly259Val substitutions have impacts
on biglycan structure (Figure 3B). Several side chains
around the mutation become translocated in MD simula-
tion. In addition, a few beta sheets on the concave region
are not maintained. The complex model suggests that the
residues in which substitutions (p.Lys147Glu and
p.Gly259Val) occur are located in the concave region of
biglycan and that biglycan binds to TGF-b through its
concave region (Figure 3C). In particular, biglycan inter-
acts with TGF-b through the Lys147 residue of biglycan
through several polar interactions (Figure 3D). The
p.Lys147Glu substitution causes a considerable polarity
change because lysine has a positive-charged side chain
and glutamic acid has a negative-charged side chain.
We found that polar interactions between biglycan and
TGF-b are removed when p.Lys147Glu substitution
has occurred (Figure 3D). These results indicate that
p.Lys147Glu substitution might reduce the binding
affinity between biglycan and TGF-b by changing the
interface polarity of biglycan and interfering with polar
interactions with TGF-b. The position of the p.Gly259Val
substitution does not seem to participate directly in
the binding interaction (Figure S3). However, it might
change the overall biglycan structure, disturbing binding
interaction with TGF-b. The MD simulation performed
on the complex model showed that p.Gly259Val does
not interact with TGF-b (Figure S3). The binding between
biglycan and TGF-b is specific for TGF-b out of severalThe Americother growth factors, which suggests an important role
for these small proteoglycans in regulating the activity
of TGF-b in the synthesis of matrix components.13
In addition, there might be some matrix disruption
caused by biglycan dysfunction because biglycan is an
important constituent of the matrix and organizes the
assembly of extracellular matrix by binding to collagen
fibrils.7,10
To investigate the functional consequences of the BGN
mutation, dermal fibroblasts were obtained from the
Korean family. Variant biglycan (p.Lys147Glu) was ex-
pressed in lower levels in an affected person (IV-1) than
in an unaffected person’s dermal fibroblasts (III-2)
(Figure S4A). The transcription of variant BGN mRNA
did not show the differences between two fibroblasts.
On the other hand, biglycan was degraded more rapidly
in IV-1’s fibroblasts than in III-2’s fibroblasts
(Figure S4B). Missense mutation can lead to the misfold-
ing of variant proteins and reduction of the protein sta-
bility.14 The decreased protein level of variant biglycan
in affected person’s cells might alter the extracellular
signaling of TGF-b, which induced the phenotype of
affected individuals.
To conclude, we describe XLR SEMD and define its
biglyan-related molecular basis in individuals from three
different ethnic backgrounds. Structural simulation studies
of the two biglycan substitution indicate functional
alterations in both cases. Further clinical, genetic, and
biological studies are necessary to understand the pa-
thological mechanism of the disease. A more detailed
understanding of the physicochemical and structural
properties of the binding sites through which biglycan in-
teracts with its various binding partners will be a critical
component of this effort.an Journal of Human Genetics 98, 1243–1248, June 2, 2016 1247
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